Pliant Therapeutics, Inc. (PLRX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Pliant Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Pliant Therapeutics, Inc. (PLRX) has returned 3.28% so far this year and -6.67% over the past 12 months.

Based on dividend-adjusted daily data since Jun 3, 2020, PLRX's average daily return is -0.01%, while the average monthly return is -0.61%.

Historically, 34% of months were positive and 66% were negative. The best month was Jul 2022 with a return of +116.9%, while the worst month was Feb 2025 at -68.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 14 months.

On a daily basis, PLRX closed higher 48% of trading days. The best single day was Jul 11, 2022 with a return of +159.0%, while the worst single day was Feb 10, 2025 at -60.6%.

Pliant Therapeutics, Inc. has an annualized alpha of -14.27%, beta of 0.97, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since June 04, 2020.

• This stock participated in 186.03% of S&P 500 Index downside but only -21.56% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PLRX ranks 33 for risk / return — below 33% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Pliant Therapeutics, Inc. (PLRX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Pliant Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pliant Therapeutics, Inc. was 97.29%, occurring on Feb 5, 2026. The portfolio has not yet recovered.

The current Pliant Therapeutics, Inc. drawdown is 96.87%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Pliant Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Pliant Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.